Nalaganje...
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...
Shranjeno v:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley
2019-08-01
|
| Serija: | CPT: Pharmacometrics & Systems Pharmacology |
| Online dostop: | https://doi.org/10.1002/psp4.12415 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|